Successful management of post-COVID-19 acanthamoebic encephalitis

•Acanthamoebic encephalitis is a rare and highly fatal disease.•COVID-19 causes immune dysregulation that may predispose to this infection.•No standard treatment regimen exists.•A combination medical therapy (trophicidal plus cysticidal) should be used.•Surgical excision of the abscess should be per...

Full description

Saved in:
Bibliographic Details
Published in:International journal of infectious diseases 2021-09, Vol.110, p.226-228
Main Authors: Siripurapu, Govinda, Samad, Sameer Abdul, Fatima, Saman, Wig, Naveet, Srivastava, M.V. Padma
Format: Article
Language:English
Subjects:
Acanthamoeba
acanthamoebic encephalitis
Case Report
COVID-19
Encephalitis
Humans
Male
miltefosine
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Acanthamoebic encephalitis is a rare and highly fatal disease.•COVID-19 causes immune dysregulation that may predispose to this infection.•No standard treatment regimen exists.•A combination medical therapy (trophicidal plus cysticidal) should be used.•Surgical excision of the abscess should be performed whenever possible. Acanthamoebic encephalitis is a rare and highly fatal disease that has no standard management protocol. Coronavirus disease 2019 (COVID-19) causes immune dysfunction and may predispose patients to this infection. The present study describes successful management of acanthamoebic encephalitis in a young male who recently recovered from COVID-19 using a combination of medical and surgical approaches. A combination of miltefosine with other agents with trophicidal and cysticidal activities should be used in the regimen. Surgical excision of the abscess should be undertaken whenever feasible.
ISSN:1201-9712
1878-3511
DOI:10.1016/j.ijid.2021.07.046